Modeling human tumors

CAMBRIDGE, Mass.—At the recent AACR meeting, AVEO Pharmaceuticals announced the development of fully human breast tumors in mice

Randall C Willis
CAMBRIDGE, Mass.—At the recent meeting of the American Association for Cancer Research, AVEO Pharmaceuticals announced the development of the first platform for the generation of fully human breast tumors in mice. According to company scientists, the Human-in-Mouse (HIM) system is a significant improvement over current xenograph models of human breast cancer and should facilitate more realistic efficacy studies in preclinical drug testing.
 
Dr. Murray Robinson, AVEO's vice president of oncology, presented the HIM model system as part of a symposium titled: Modeling Abnormal Proliferation in Model Organisms. "As we further develop our portfolio of novel oncology products, such as AV-412, the HIM system and AVEO's proprietary Human Response Prediction platform will help us design clinical trials with a higher likelihood of success," said Tuan Ha-Ngoc, president and CEO of AVEO.

Randall C Willis

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022